The efficacy of intranasal oxytocin before applied behavior analysis (ABA) therapy with autistic spectrum disorder

Phase 3

Not yet recruiting

• Conditions: Autism.; Autistic disorder; F84.0

• Registration Number: IRCT20211004052670N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

autism
4-17 year old

Exclusion Criteria

endocrine disease
head thruma
neurologic problem

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of autism. Timepoint: Before the intervention, the sixth week during the intervention and 6 weeks after the intervention. Method of measurement: Gilliam Autism Rating Scale (GARS).;Strenght and Difficulties. Timepoint: Before the intervention, the sixth week during the intervention and 6 weeks after the intervention. Method of measurement: Strengths and Difficulties Questionnaire (SDQ).